LBTAAC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
LBT Innovations Limited - Option Expiring 28-Nov-2024 Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in LBTAAC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in LBTAAC
N/A
LBTAAC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in LBTAAC also invest in...
Want more shares? Try these...
LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia and currently employs 40 full-time employees. The company went IPO on 2006-07-31. Its principal activities includes researching, developing, and commercializing technologies for the healthcare and laboratory supply markets. Its capabilities include artificial intelligence (AI), image analysis and software engineering solutions that improve medical diagnostic workflows. Its Automated Plate Assessment System (APAS) is a platform technology that automates culture-plate screening and interpretation. Its products include APAS Independence and APAS Analysis Modules. The APAS Independence combines AI, software and imaging analysis to create a platform technology for intelligent image interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. Its pipeline includes APAS- antimicrobial resistance (AMR) Analysis Module, Automated Gram Stain Assessment, Biofilm, MicroStreak and WoundVue.
📊 Share price